Status:
UNKNOWN
Risk Stratification Using PET in HCM
Lead Sponsor:
Region Gävleborg
Collaborating Sponsors:
Landstinget i Värmland
Dalarna County Council, Sweden
Conditions:
Hypertrophic Cardiomyopathy
Eligibility:
All Genders
18+ years
Brief Summary
The overall rationale is to reduce the risk of sudden cardiac death in individuals with hypertrophic cardiomyopathy (HCM). The novel approach of this study is to correlate Positron Emission Tomography...
Detailed Description
Positron Emission Tomography (PET) is a functional imaging technique that utilizes radioactive tracers to gain information on physiological or pathophysiological processes in vivo. Different tracers c...
Eligibility Criteria
Inclusion
- Hypertrophic cardiomyopathy, implantable cardioverter defibrillator, informed consent
Exclusion
- Patients younger than 18 years, pregnancy, breast feeding, claustrophobia, intolerance/allergic reaction to adenosin or mannitol, severe hypotension, unstable angina pectoris, incompensated systolic heart failure, increased intracranial pressure, hypovolemia, dipyramidole.
Key Trial Info
Start Date :
May 3 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 3 2018
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03278457
Start Date
May 3 2017
End Date
June 3 2018
Last Update
September 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Region Gavleborg
Gävle, Sweden, 80324